• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Survey: France Biotech recommends policies to develop innovative life sciences companies

Survey: France Biotech recommends policies to develop innovative life sciences companies

December 18, 2014
CenterWatch Staff

France Biotech, an association of entrepreneurs in the life sciences industry, has published the twelfth edition of its annual survey, Panorama of the Life Sciences Industry, which outlines the industry's major trends for 2013 and 2014 in France and worldwide. This year, 214 French companies took part in the study. France Biotech included multiple recommendations to foster excellence in the life sciences industry.

"Our SMEs have a very high level of technical expertise and efficiency, allowing them to quickly bring numerous projects to advanced stages of development,” said Pierre-Olivier Goineau, president of France Biotech. “This wealth has convinced stock market investors to invest in our industry, a unique phenomenon in Europe that rewards SMEs founded in the 2000s. These success stories belong to outstanding entrepreneurs and their venture capital investors, and are a sign of both maturity and promising growth potential.”

“However, our youngest companies are struggling; venture capital investors are fewer and have less power than they used to,” said Groineau. “The entire funding chain is fragile, and the serious lack of incentives to channel French household savings toward innovative companies can't be fully compensated by the efforts of Bpifrance (a public investment bank)."

"In order for our innovations to stir economic growth and job creation, some obstacles blocking our way ought to be removed. These include excessive paperwork and administrative tasks when dealing with multiples layers of academic institutions; delays in applying to CIR (the Research Tax Credit, a French tax incentive mechanism to support investments in SMEs); a lack of understanding of the specificities of our industry from the ANSM (the French Agency for the Safety of Health Products, whose task is to assess the risks posed by new health products); scarcity of the dialogue with the public health authorities; suppression of the Precautionary Principle that generates fears," said Goineau.

France Biotech has recommended policies to promote the development of innovative companies in the life sciences. These include: 

  • Placing the innovation in life sciences at the heart of public health policies
  • Strengthen and develop the number of venture capital investment funds by channeling 5% of the French households' life insurance toward investments into innovative companies
  • Adapt the lifespan of FCICs (a French form of mutual fund) and the status of JEI (a program supporting innovative companies' R&D investments, including through tax breaks) to the investment cycle, which is longer than in other sectors, a disadvantage made worse by the current status quo
  • Promoting the hiring of young academics using CIR and the JEI status
  • Fostering contractual agreements with academic partners by streamlining the current practices and removing the multiple layers of supervision by various academic institutions
  • Improving competitiveness by lowering taxes related to BSAs (stock warrants) and by extending the BSPCEs (founders' warrants) to all SMEs.

Since 2002, France Biotech has conducted the Panorama of the Life Sciences Industry in France, a study that provides an annual update on the growth and dynamism of this sector in France. The results of this study allow France Biotech to ground its proposals to the government in hard facts and to effectively represent the entire industry.

The Panorama analyzes data from independent companies allocating at least 15% of total spending to R&D costs. France Biotech surveyed more than 450 companies via a secure online questionnaire and has analyzed the data provided from 214 of the 255 total responses.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing